Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients
Small cell lung cancer (SCLC) is a highly aggressive cancer with a dismal 5‐year survival of < 7%, despite the addition of immunotherapy to first‐line chemotherapy. Specific tumor biomarkers, such as delta‐like ligand 3 (DLL3) and schlafen11 (SLFN11), may enable the selection of more efficacious,...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-07-01
|
| Series: | Molecular Oncology |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/1878-0261.13696 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|